Free CME from PeerView
Continuing Pharmacy Education (CPE) Activities
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
StartThis activity expired on August 1, 2024; credit is no longer available.
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
- Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
- Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute
Columbus, Ohio
Jennifer Woyach, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene;
Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave
Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics;
Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.;
Schrödinger, Inc.; and Verastem Oncology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 1, 2024; credit is no longer available.
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
- Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
- Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute
Columbus, Ohio
Jennifer Woyach, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene;
Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave
Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics;
Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.;
Schrödinger, Inc.; and Verastem Oncology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
StartThis activity expired on June 28, 2024; credit is no longer available.
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes
Activity Description
In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.
Target Audience
This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland
Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co.,
Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC
Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
David Martin
Patient/Advocate
David Martin has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Shawnte' Spriggs
Patient/Advocate
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 28, 2024; credit is no longer available.
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes
Activity Description
In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.
Target Audience
This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland
Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co.,
Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC
Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
David Martin
Patient/Advocate
David Martin has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Shawnte' Spriggs
Patient/Advocate
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
StartThis activity expired on July 2, 2024; credit is no longer available.
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
Activity Description and Educational Objectives
Recent research and improved understanding of the pathogenesis of multiple
sclerosis (MS) has led to the development of multiple biomarkers and imaging
modalities that can improve clinicians’ ability to individualize therapy
through more effective monitoring of disease progression and treatment
response. The promise of eventually arriving at data-driven personalized
care—coupled with the number of available and emerging therapies for MS
treatment—makes it more important than ever that clinicians remain up-to-date
on advances in biomarkers and imaging approaches, as well as shared
decision-making strategies.
In this activity, based on a recent live symposium, MS experts cover the
latest data on these new and emerging biomarkers for MS management. Using
examples from their own practice, the panelists also discuss ways to
incorporate these biomarker findings into individualized treatment decisions
to empower patients and improve treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
- Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
- Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers
Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis
Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada;
and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono
Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and
Sanofi/Genzyme Canada Inc.
Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado
Kathleen M. Costello, RN, MS, NP, MSCN, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6939-23-T.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 2, 2024; credit is no longer available.
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
Activity Description and Educational Objectives
Recent research and improved understanding of the pathogenesis of multiple
sclerosis (MS) has led to the development of multiple biomarkers and imaging
modalities that can improve clinicians’ ability to individualize therapy
through more effective monitoring of disease progression and treatment
response. The promise of eventually arriving at data-driven personalized
care—coupled with the number of available and emerging therapies for MS
treatment—makes it more important than ever that clinicians remain up-to-date
on advances in biomarkers and imaging approaches, as well as shared
decision-making strategies.
In this activity, based on a recent live symposium, MS experts cover the
latest data on these new and emerging biomarkers for MS management. Using
examples from their own practice, the panelists also discuss ways to
incorporate these biomarker findings into individualized treatment decisions
to empower patients and improve treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
- Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
- Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers
Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis
Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada;
and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono
Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and
Sanofi/Genzyme Canada Inc.
Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado
Kathleen M. Costello, RN, MS, NP, MSCN, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6939-23-T.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
StartThis activity expired on July 1, 2024; credit is no longer available.
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes
Program Overview
Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
- Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
- Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance
and submission of the activity evaluation form. Partial credit may be awarded
for ACPE credit. A statement of credit will be available upon completion of
an online evaluation/claimed credit form at www.lipid.org/cme. The deadline
to claim credit is July 1, 2024.
For Pharmacists: Upon receipt of the completed activity evaluation
form, transcript information will be available at www.mycpemonitor.net within
4 weeks.
*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit
requested after this date will be subject to a fee by the accreditation
board.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Designation
CME Credit Provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physician Credit Designation Statement
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.
Pharmacists
This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).
Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
For the advanced practice nurse, pharmacotherapy hours will be calculated on
your certificate.
Faculty
Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon
P. Barton Duell, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis
Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC;
Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.;
REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.
Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial
interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Copyright © 2000-2023, PeerView
This activity expired on July 1, 2024; credit is no longer available.
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes
Program Overview
Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
- Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
- Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance
and submission of the activity evaluation form. Partial credit may be awarded
for ACPE credit. A statement of credit will be available upon completion of
an online evaluation/claimed credit form at www.lipid.org/cme. The deadline
to claim credit is July 1, 2024.
For Pharmacists: Upon receipt of the completed activity evaluation
form, transcript information will be available at www.mycpemonitor.net within
4 weeks.
*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit
requested after this date will be subject to a fee by the accreditation
board.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Designation
CME Credit Provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physician Credit Designation Statement
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.
Pharmacists
This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).
Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
For the advanced practice nurse, pharmacotherapy hours will be calculated on
your certificate.
Faculty
Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon
P. Barton Duell, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis
Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC;
Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.;
REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.
Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial
interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Copyright © 2000-2023, PeerView
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
StartThis activity expired on June 30, 2024; credit is no longer available.
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of multiple sclerosis (MS) requires selecting
medications that safely and effectively target different aspects of
pathophysiology and offer choices in administration, risk/benefit balance,
and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an
emerging class of disease-modifying therapies that affect processes mediated
by B cells and myeloid cells, which are contributors to the inflammation and
neurodegeneration that drive MS. BTK inhibitors are a novel class in MS
management with four agents currently in phase 3 trials. As such, clinicians
must remain up to date with the latest data on the rationale for their use
and trial findings on the efficacy, safety, and tolerability of this
promising line of treatment.
At a recent PeerView live event, MS experts shared relevant stories from
their practice to highlight the rationale for the use of BTK inhibitors in
MS, as well as perspectives on potential applications in clinical care and
the latest data from clinical trials on BTK inhibition.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
- Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
- Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics,
Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen
Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC;
Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and
Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis
Pharmaceuticals Corporation (paid to institution).
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La
Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada
Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 30, 2024; credit is no longer available.
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of multiple sclerosis (MS) requires selecting
medications that safely and effectively target different aspects of
pathophysiology and offer choices in administration, risk/benefit balance,
and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an
emerging class of disease-modifying therapies that affect processes mediated
by B cells and myeloid cells, which are contributors to the inflammation and
neurodegeneration that drive MS. BTK inhibitors are a novel class in MS
management with four agents currently in phase 3 trials. As such, clinicians
must remain up to date with the latest data on the rationale for their use
and trial findings on the efficacy, safety, and tolerability of this
promising line of treatment.
At a recent PeerView live event, MS experts shared relevant stories from
their practice to highlight the rationale for the use of BTK inhibitors in
MS, as well as perspectives on potential applications in clinical care and
the latest data from clinical trials on BTK inhibition.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
- Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
- Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics,
Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen
Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC;
Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and
Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis
Pharmaceuticals Corporation (paid to institution).
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La
Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada
Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
StartThis activity expired on May 18, 2024; credit is no longer available.
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
- Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
- Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina
Patrick A. Flume, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi
USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis
Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck &
Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals
Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata
Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen
Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals;
and Vertex Pharmaceuticals Incorporated.
Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado
Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Susan Palmer
Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Insmed.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 18, 2024; credit is no longer available.
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
- Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
- Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina
Patrick A. Flume, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi
USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis
Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck &
Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals
Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata
Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen
Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals;
and Vertex Pharmaceuticals Incorporated.
Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado
Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Susan Palmer
Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Insmed.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
StartThis activity expired on May 10, 2024; credit is no longer available.
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes
Activity Description
An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.
Target Audience
This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
- Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
- Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada
Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals;
Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services, Inc.; Novo Nordisk
Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer;
Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda
Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals,
Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL
Behring.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru
Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals
U.S.A., Inc.
Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy
Francesco Saccà, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and
Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.
Patient/Planner
Kaitlin Stockwell Masters
Kaitlin Stockwell Masters has a financial interest/relationship or
affiliation in the form of:
Speaker for argenx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 10, 2024; credit is no longer available.
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes
Activity Description
An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.
Target Audience
This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
- Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
- Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada
Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals;
Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services, Inc.; Novo Nordisk
Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer;
Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda
Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals,
Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL
Behring.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru
Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals
U.S.A., Inc.
Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy
Francesco Saccà, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and
Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.
Patient/Planner
Kaitlin Stockwell Masters
Kaitlin Stockwell Masters has a financial interest/relationship or
affiliation in the form of:
Speaker for argenx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care
StartThis activity expired on May 25, 2024; credit is no longer available.
Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care
Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes
Activity Description
The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.
Target Audience
This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
- Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
- Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California
Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California
Ian Neel, MD, has a financial interest/relationship or affiliation in the
form of:
Consultant and/or Advisor for Centene Corporation/Health Net
Pharmacy and Therapeutics Committee.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application
Psychologists
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/APA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 25, 2024; credit is no longer available.
Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care
Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes
Activity Description
The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.
Target Audience
This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
- Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
- Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California
Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California
Ian Neel, MD, has a financial interest/relationship or affiliation in the
form of:
Consultant and/or Advisor for Centene Corporation/Health Net
Pharmacy and Therapeutics Committee.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application
Psychologists
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/APA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy
StartThis activity expired on May 13, 2024; credit is no longer available.
Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy
Media: Enduring Material
Activity Release Date: April 14, 2023
Activity Expiration Date: May 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM!
Target Audience
This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents
- Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM
- Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Professor, Hematology/Medical Oncology and Pharmacology and Chemical
Biology
Emory University School of Medicine
Medical Director, Clinical Trials Office
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen and GlaxoSmithKline.
Grant/Research Support from Abbisko Therapeutics; AbbVie; Actuate
Therapeutics, Inc.; Amgen; AstraZeneca; Bayer Corporation; Bristol Myers
Squibb; Genmab A/S; GlaxoSmithKline; Infinity Pharmaceuticals, Inc.; Inhibrx,
Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mersana Therapeutics;
Meryx; MorphoSys; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron
Pharmaceuticals Inc.; Sanofi; Sutro Biopharma, Inc.; Takeda Pharmaceutical
Company Limited; Turning Point Therapeutics, Inc. and Xencor, Inc. Research
funding to institution.
Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP
Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematologic Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Kansas City, Kansas
Zahra Mahmoudjafari, PharmD, MBA, BCOP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Incyte
Corporation; Kite Pharma; Merck & Co., Inc.; Omeros Corporation; Sanofi; and
Seagen Inc.
Speaker for Omeros Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Sanofi.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-036-H01-P
Type of Activity: Application
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 13, 2024; credit is no longer available.
Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy
Media: Enduring Material
Activity Release Date: April 14, 2023
Activity Expiration Date: May 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM!
Target Audience
This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents
- Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM
- Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Professor, Hematology/Medical Oncology and Pharmacology and Chemical
Biology
Emory University School of Medicine
Medical Director, Clinical Trials Office
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen and GlaxoSmithKline.
Grant/Research Support from Abbisko Therapeutics; AbbVie; Actuate
Therapeutics, Inc.; Amgen; AstraZeneca; Bayer Corporation; Bristol Myers
Squibb; Genmab A/S; GlaxoSmithKline; Infinity Pharmaceuticals, Inc.; Inhibrx,
Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mersana Therapeutics;
Meryx; MorphoSys; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron
Pharmaceuticals Inc.; Sanofi; Sutro Biopharma, Inc.; Takeda Pharmaceutical
Company Limited; Turning Point Therapeutics, Inc. and Xencor, Inc. Research
funding to institution.
Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP
Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematologic Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Kansas City, Kansas
Zahra Mahmoudjafari, PharmD, MBA, BCOP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Incyte
Corporation; Kite Pharma; Merck & Co., Inc.; Omeros Corporation; Sanofi; and
Seagen Inc.
Speaker for Omeros Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Sanofi.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-036-H01-P
Type of Activity: Application
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Critical Conversations on Atrial Fibrillation: A MasterClass Series
StartThis activity expired on April 3, 2024; credit is no longer available.
Critical Conversations on Atrial Fibrillation: A MasterClass Series
Activity Description and Educational Objectives
Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF.
Upon completion of this activity, participants should be better able to:
- Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society
- Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology
- Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics
Target Audience
This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other clinicians involved in the care of patients with or at risk for AF.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: April 4, 2023 - April 3, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Co-Chairs & Presenters
Sean Pokorney, MD, MBA
Assistant Professor of Medicine
Director of the Arrhythmia Core Laboratory
Duke Clinical Research Institute
Duke University
Raleigh, North Carolina
Sean Pokorney, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Boston Scientific Corporation; Bristol
Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Grant/Research Support from Boston Scientific Corporation; Bristol
Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Speakers Bureau participant with Boston Scientific Corporation;
Medtronic; Phillips Healthcare Corporation; Sanofi; and Zoll.
Emily P. Zeitler, MD, MHS, FACC, FHRS
Clinical Electrophysiology
Dartmouth Health
Assistant Professor of Medicine
Geisel School of Medicine
Assistant Professor of Health Care Policy
The Dartmouth Institute
Lebanon, New Hampshire
Emily P. Zeitler, MD, MHS, FACC, FHRS, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Biosense Webster Inc.; and
Medtronic.
Grant/Research Support from Biosense Webster Inc. (Johnson & Johnson
Services, Inc.); Boston Scientific Corporation; and Sanofi.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6923-23-T.
Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-030-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on April 3, 2024; credit is no longer available.
Critical Conversations on Atrial Fibrillation: A MasterClass Series
Activity Description and Educational Objectives
Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF.
Upon completion of this activity, participants should be better able to:
- Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society
- Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology
- Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics
Target Audience
This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other clinicians involved in the care of patients with or at risk for AF.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: April 4, 2023 - April 3, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Co-Chairs & Presenters
Sean Pokorney, MD, MBA
Assistant Professor of Medicine
Director of the Arrhythmia Core Laboratory
Duke Clinical Research Institute
Duke University
Raleigh, North Carolina
Sean Pokorney, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Boston Scientific Corporation; Bristol
Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Grant/Research Support from Boston Scientific Corporation; Bristol
Myers Squibb; Medtronic; Pfizer; and Phillips Healthcare Corporation.
Speakers Bureau participant with Boston Scientific Corporation;
Medtronic; Phillips Healthcare Corporation; Sanofi; and Zoll.
Emily P. Zeitler, MD, MHS, FACC, FHRS
Clinical Electrophysiology
Dartmouth Health
Assistant Professor of Medicine
Geisel School of Medicine
Assistant Professor of Health Care Policy
The Dartmouth Institute
Lebanon, New Hampshire
Emily P. Zeitler, MD, MHS, FACC, FHRS, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Biosense Webster Inc.; and
Medtronic.
Grant/Research Support from Biosense Webster Inc. (Johnson & Johnson
Services, Inc.); Boston Scientific Corporation; and Sanofi.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6923-23-T.
Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-030-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy
StartThis activity expired on April 29, 2024; credit is no longer available.
Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy
Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
- Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
- Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio
Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen
Pharmaceuticals, Inc.
Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical
Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York
Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee
Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on April 29, 2024; credit is no longer available.
Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy
Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
- Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
- Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio
Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen
Pharmaceuticals, Inc.
Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical
Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York
Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee
Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView